摘要
黑色素瘤抑制活性(MIA)蛋白质被恶性黑素瘤细胞强烈表达和分泌,并显示出促进黑素瘤的发生和侵袭。MIA蛋白是第一个细胞外蛋白,显示在溶液中可以结合纤连蛋白III型结构域的Src同源3(SH3)结构域样折叠。与MIA一起,同源蛋白OTOR(或FDP),MIA-2和TANGO(或MIA-3)构成非胞质的蛋白质家族,除了全长TANGO和TANGO1样(TALI) - 细胞外SH3- 含有蛋白质的结构域。蛋白质家族的成员调节胶原成熟和出口,软骨发育,细胞外基质中的细胞附着和黑素瘤转移。因此,这些蛋白质可以用作针对恶性黑素瘤的药物开发的有希望的靶标。 在过去二十年中,NMR光谱已经成为药物化学中的有力技术。虽然传统的高通量筛选仅报告了低分子化合物的活性或亲和力,NMR光谱不仅涉及具有其活性的那些化合物的结构,而且还可以解开蛋白上配体结合位点的结构信息 原子分辨率。基于配体与其靶蛋白之间的相互作用的分子细节,可以更有效地进一步改进初始片段命中的结合亲和力,以产生具有显着疗效的铅结构。基于NMR的方法有望大大有助于寻求低分子量化合物,最终可以产生药物以更有效地治疗皮肤相关疾病如恶性黑素瘤。
关键词: NMR
Current Medicinal Chemistry
Title:NMR-based Drug Development and Improvement Against Malignant Melanoma – Implications for the MIA Protein Family
Volume: 24 Issue: 17
关键词: NMR
摘要: The Melanoma Inhibitory Activity (MIA) protein is strongly expressed and secreted by malignant melanoma cells and was shown to promote melanoma development and invasion. The MIA protein was the first extracellular protein shown to adopt an Src homology 3 (SH3) domain-like fold in solution that can bind to fibronectin type III domains. Together with MIA, the homologous proteins OTOR (or FDP), MIA-2, and TANGO (or MIA-3) constitute a protein family of non-cytosolic and – except for fulllength TANGO and TANGO1-like (TALI) – extracellular SH3-domain containing proteins. Members of this protein family modulate collagen maturation and export, cartilage development, cell attachment in the extracellular matrix, and melanoma metastasis. These proteins may thus serve as promising targets for drug development against malignant melanoma.
For the last twenty years, NMR spectroscopy has become a powerful technique in medicinal chemistry. While traditional high throughput screenings only report on the activity or affinity of low molecular weight compounds, NMR spectroscopy does not only relate to the structure of those compounds with their activity, but it can also unravel structural information on the ligand binding site on the protein at atomic resolution. Based on the molecular details of the interaction between the ligand and its target protein, the binding affinities of initial fragment hits can be further improved more efficiently in order to generate lead structures that exhibit significant therapeutic effects. The NMR-based approach promises to greatly contribute to the quest for low molecular weight compounds that ultimately could yield drugs to treat skin-related diseases such as malignant melanoma more effectively.Export Options
About this article
Cite this article as:
NMR-based Drug Development and Improvement Against Malignant Melanoma – Implications for the MIA Protein Family, Current Medicinal Chemistry 2017; 24 (17) . https://dx.doi.org/10.2174/0929867324666170608104347
DOI https://dx.doi.org/10.2174/0929867324666170608104347 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transcription, DNA Damage and Beyond: The Roles of Histone Ubiquitination and Deubiquitination
Current Protein & Peptide Science Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
Current Cancer Drug Targets Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects
Current Pharmaceutical Design Is Tretinoin Still a Key Agent for Photoaging Management?
Mini-Reviews in Medicinal Chemistry Current Drug Therapy for Prostate Cancer: An Overview
Current Medicinal Chemistry - Anti-Cancer Agents Radiological Screening Programs for Women at High Risk of Developing Breast Cancer
Current Women`s Health Reviews Brief Messages to Promote Prevention and Detection of Sexually Transmitted Infections
Current HIV Research Biosystems Engineering of Prokaryotes with Tumor-Killing Capacities
Current Pharmaceutical Design Expression and Function of Bcl-2 Proteins in Melanoma
Current Genomics MicroRNA: Biogenesis, Function and Role in Cancer
Current Genomics Genetics of Bladder Malignant Tumors in Childhood
Current Genomics Restoration of Antitumor Immunity Through Selective Inhibition of Myeloid Derived Suppressor Cells by Anticancer Therapies
Current Molecular Medicine Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
Mini-Reviews in Medicinal Chemistry CETUXIMAB: From Bench to Bedside
Current Cancer Drug Targets Combination of DC Vaccine and Conventional Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Mandatory Reporting of Coronary Artery Calcifications Incidentally Noted on Chest Multi-Detector Computed Tomography: A Multicentre Experience
Current Vascular Pharmacology Adiponectin as a Potential Therapeutic Target for Prostate Cancer
Current Pharmaceutical Design Reducing False Positive Findings in Statistical Analysis of Pharmacogenomic Biomarker Studies Using High-Throughput Technologies
Current Drug Safety Peptimmunology: Immunogenic Peptides and Sequence Redundancy
Current Drug Discovery Technologies IAPs as a Target for Anticancer Therapy
Current Cancer Drug Targets